Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Veklury Declines As COVID-19 Demand Eases
Executive Summary
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
You may also be interested in...
Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.
With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape
The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.
Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.